Search results for "Drug synergism"

showing 10 items of 144 documents

Synergistic effect of recombinant CD4-immunoglobulin in combination with azidothymidine, dideoxyinosine and 0.5 beta-monoclonal antibody on human imm…

1994

Data are presented which indicate that combinations of rCD4 immunoglobulin with azidothymidine, dideoxyinosine or 0.5 beta mouse monoclonal antibodies directed against the V3 region of HIV-1, were more effective in treatment of acute HIV infection in vitro than each compound alone. It is suggested that combination therapy with these compounds is more beneficial in treatment of HIV-infected patients than monotherapy, especially with respect to a reduction of the known side effects and the formation of resistant HIV strains after treatment with nucleoside analogues.

Combination therapymedicine.drug_classmedicine.medical_treatmentHIV InfectionsBiologyMonoclonal antibodyApplied Microbiology and BiotechnologyVirusZidovudinemedicineHumansLymphocytesCells Culturedvirus diseasesAntibodies MonoclonalDrug SynergismImmunotherapyVirologyIn vitroAnti-Bacterial AgentsDidanosinebiology.proteinDrug Therapy CombinationAntibodyNucleosideZidovudineCD4 Immunoadhesinsmedicine.drugLetters in applied microbiology
researchProduct

Anti-Hypotensive Treatment and Endothelin Blockade Synergistically Antagonize Exercise Fatigue in Rats under Simulated High Altitude

2013

Rapid ascent to high altitude causes illness and fatigue, and there is a demand for effective acute treatments to alleviate such effects. We hypothesized that increased oxygen delivery to the tissue using a combination of a hypertensive agent and an endothelin receptor A antagonist drugs would limit exercise-induced fatigue at simulated high altitude. Our data showed that the combination of 0.1 mg/kg ambrisentan with either 20 mg/kg ephedrine or 10 mg/kg methylphenidate significantly improved exercise duration in rats at simulated altitude of 4,267 m, whereas the individual compounds did not. In normoxic, anesthetized rats, ephedrine alone and in combination with ambrisentan increased heart…

Critical Care and Emergency MedicinePulmonologyPhysiologyAcclimatizationRespiratory Systemlcsh:MedicineAltitude SicknessPharmacologyCardiovascular PhysiologyDrug DiscoveryMedicine and Health SciencesDrug InteractionsSympathomimeticslcsh:ScienceFatigueAltitude sicknessEphedrineMammalsMultidisciplinaryPhenylpropionatesAltitudeDrug SynergismHematologyAnimal ModelsCell HypoxiaPyridazinesmedicine.anatomical_structureVertebratesBlood CirculationDrug Therapy CombinationAnatomymedicine.symptomEndothelin receptorPerfusionInjections IntraperitonealResearch Articlemedicine.drugDrug Research and DevelopmentAmbrisentanEndothelin A Receptor AntagonistsCardiologyEnvironmental and Occupational Lung DiseasesResearch and Analysis MethodsRodentsCardiovascular PharmacologyModel OrganismsHeart ratemedicineAnimalsRespiratory PhysiologySports and Exercise MedicinePharmacologyDose-Response Relationship Drugbusiness.industryAcute Cardiovascular Problemslcsh:ROrganismsHemodynamicsBiology and Life SciencesSkeletal muscleHypoxia (medical)medicine.diseaseRatsDisease Models AnimalBlood pressureMethylphenidateCardiovascular Anatomylcsh:QClinical MedicinebusinessPLoS ONE
researchProduct

Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease

2013

Background Glucocorticoid functions are markedly impaired in patients with chronic obstructive pulmonary disease (COPD). The phosphodiesterase 4 inhibitor roflumilast N-oxide (RNO) is the active metabolite of roflumilast approved as a treatment to reduce the risk of exacerbations in patients with severe COPD. Objective We sought to characterize the differential effects of RNO versus corticosteroids and their potential additive/synergistic effect in neutrophils from patients with COPD, thus providing scientific rationale for the combination of roflumilast with corticosteroids in the clinic. Methods Peripheral blood neutrophils were isolated from patients with COPD (n = 32), smokers (n = 7), …

CyclopropanesLipopolysaccharidesMaleMAPK/ERK pathwaymedicine.medical_specialtyNeutrophilsPrimary Cell CultureImmunologyDrug ResistanceAminopyridinesGene ExpressionComplex MixturesDexamethasoneHistone DeacetylasesPhosphatidylinositol 3-KinasesPulmonary Disease Chronic ObstructiveGlucocorticoid receptorAdrenal Cortex HormonesInternal medicineTobaccomedicineHumansImmunology and AllergyMacrophage Migration-Inhibitory FactorsDexamethasoneActive metaboliteRoflumilastAgedCOPDbusiness.industryInterleukin-8Drug SynergismMiddle Agedmedicine.diseaseIntramolecular OxidoreductasesEndocrinologyMatrix Metalloproteinase 9BenzamidesMitogen-Activated Protein Kinase PhosphatasesFemaleMacrophage migration inhibitory factorPhosphodiesterase 4 InhibitorsbusinessBiomarkersGlucocorticoidmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro

2012

Maintaining graft versus leukemia (GvL) and antivirus responses of cytotoxic T cells (CTLs) while suppressing graft-versus-host disease (GvHD) remains a challenge after allogeneic bone marrow transplantation. Clinical observations indicate that combining glucocorticoids with multi-tyrosine-kinase inhibitors could be a successful therapeutic approach. We and others have shown that the BCR-ABL/SRC kinase inhibitor dasatinib may enhance or suppress T cells in vitro. In this report, we evaluated combination effects of dasatinib and dexamethasone on CD3 + and virus-specific CD8 + T cells directly ex vivo and on antigen-specific leukemia-reactive and alloreactive CD8 + T cell clones. Functional o…

Cytotoxicity ImmunologicHerpesvirus 4 HumanCancer ResearchNaive T cellT cellDasatinibDrug Evaluation PreclinicalReceptors Antigen T-CellCytomegalovirusApoptosisT-Cell Antigen Receptor SpecificityBiologyLymphocyte ActivationCell DegranulationDexamethasoneAntigenHLA AntigensT-Lymphocyte SubsetsGeneticsmedicineHumansCytotoxic T cellAntigens ViralProtein Kinase InhibitorsMolecular BiologyCells CulturedDegranulationDrug SynergismT-Lymphocytes Helper-InducerCell BiologyHematologyDasatinibThiazolesPyrimidinesmedicine.anatomical_structureImmunologyCancer researchCytokinesK562 CellsMemory T cellCell DivisionCD8Signal TransductionT-Lymphocytes Cytotoxicmedicine.drugExperimental Hematology
researchProduct

Interaction effects of Fusarium enniatins (A, A1, B and B1) combinations on in vitro cytotoxicity of Caco-2 cells

2014

Abstract Foodstuff is usually contaminated by more than one mycotoxin, however toxicological data are lacking as regards the effects in combinations compared to their individual effect. This study investigated the in vitro effects of enniatins (ENs) A, A1, B and B1, alone and in combinations, on Caco-2 cells viability by MTT assay after 24 h of exposure. Cells were treated with concentrations ranging from 0.9 to 15.0 μM, individually and in combination of two, three and four mycotoxins. Dose–response curves were generated for each mycotoxin and the isobologram method was used to determine the interactive effects of tested mixtures. Tested ENs produced significant cytotoxic effects both indi…

FusariumDose-Response Relationship DrugbiologyCell SurvivalChemistryDrug SynergismGeneral MedicineMycotoxinsToxicologybiology.organism_classificationInteractionIn vitroToxicologyInhibitory Concentration 50chemistry.chemical_compoundFusariumCaco-2DepsipeptidesHumansCytotoxic T cellMTT assayFood scienceCaco-2 CellsMycotoxinCytotoxicityToxicology in Vitro
researchProduct

Individual and Combined Effect of Zearalenone Derivates and Beauvericin Mycotoxins on SH-SY5Y Cells

2020

Beauvericin (BEA) and zearalenone derivatives, &alpha

FusariumMTTElectrosprayTime FactorsHealth Toxicology and MutagenesisNeurotoxinslcsh:MedicineToxicologyMass spectrometryArticleSH-SY5Y cells03 medical and health scienceschemistry.chemical_compoundInhibitory Concentration 500404 agricultural biotechnologyCell Line TumorDepsipeptidesHumansMTT assayMycotoxinZearalenone030304 developmental biologyNeurons0303 health scienceszearalenone derivatesChromatographybiologyCell DeathDose-Response Relationship Druglcsh:RbeauvericinDrug Synergism04 agricultural and veterinary sciencesbiology.organism_classification040401 food scienceBeauvericinqTOF–MS/MSchemistryZeranolAntagonismToxins
researchProduct

Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activatio…

1999

To test the Kirsten-Ras (Ki-Ras) alternative prenylation hypothesis in malignant transformation, we used a novel farnesyltransferase inhibitor competitive to farnesyl-pyrophosphate, RPR130401, and a CaaX peptidomimetic geranylgeranyltransferase-1 inhibitor GGTI-298. In Ki-Ras-overexpressing transformed adrenocortical cells, RPR130401 at 1-10 microM inhibited very efficiently the [(3)H]farnesyl but not [(3)H]geranylgeranyl transfer to Ras. However, proliferation of these cells was only slightly sensitive to RPR130401 (IC(50)=30 microM). GGTI-298 inhibited the growth of these cells with an IC(50) of 11 microM but cell lysis was observed at 15 microM. The combination of 10 microM RPR130401 and…

GeranylgeranyltransferaseFarnesyltransferaseSimvastatinIndolesTime FactorsFarnesyltransferaseBiophysicsProtein PrenylationAntineoplastic AgentsKirsten-RasBiochemistryAnti-proliferative effectS PhasePrenylationStructural BiologyAlternative pathwayAdrenal GlandsGeneticsAnimalsFarnesyltranstransferaseLovastatinBinding siteEnzyme InhibitorsMolecular BiologyCells CulturedCell Line TransformedPrenylationAlkyl and Aryl TransferasesbiologyDose-Response Relationship DrugCell growthFarnesyltransferase inhibitorG1 PhaseG1/S transitionDrug SynergismCell BiologyCell cycleFlow CytometryCell biologyRatsGenes rasBiochemistryMitogen-activated protein kinaseBenzamidesbiology.proteinras ProteinsMitogen-Activated Protein KinasesCell DivisionFEBS letters
researchProduct

Cytotoxicity and chemosensitizing activity of amphiphilic poly(glycerol)-poly(alkylene oxide) block copolymers.

2014

All polymeric chemosensitizers proposed thus far have a linear poly(ethylene glycol) (PEG) hydrophilic block. To testify whether precisely this chemical structure and architecture of the hydrophilic block is a prerequisite for chemosensitization, we tested a series of novel block copolymers containing a hyperbranched polyglycerol segment as a hydrophilic block (PPO-NG copolymers) on multi-drug-resistant (MDR) tumor cells in culture. PPO-NG copolymers inhibited MDR of three cell lines, indicating that the linear PEG can be substituted for a hyperbranched polyglycerol block without loss of the polymers' chemosensitizing activity. The extent of MDR reversal increased with the polymers affinity…

GlycerolPolymers and PlasticsCell SurvivalPolymersBioengineeringAntineoplastic AgentsMicellePolyethylene GlycolsBiomaterialschemistry.chemical_compoundInhibitory Concentration 50Polymer chemistryAmphiphilePEG ratioMaterials ChemistryCopolymerHumansATP Binding Cassette Transporter Subfamily B Member 1CytotoxicityMicelleschemistry.chemical_classificationDrug SynergismPolymerPoloxamerDrug Resistance MultiplechemistryDoxorubicinDrug Resistance NeoplasmMCF-7 CellsDrug Screening Assays AntitumorK562 CellsEthylene glycolHydrophobic and Hydrophilic InteractionsBiomacromolecules
researchProduct

H89 enhances the sensitivity of cancer cells to glyceryl trinitrate through a purinergic receptor-dependent pathway

2014

// Marion Cortier 1, 2, 3 , Rahamata Boina-Ali 1, 2, 3 , Cindy Racoeur 1, 2, 3 , Catherine Paul 1, 2, 3 , Eric Solary 2, 4, 5 , Jean-Francois Jeannin 1, 2, 3 , Ali Bettaieb 1, 2, 3 1 EPHE, Tumor Immunology and Immunotherapy Laboratory, Dijon, F-21000, France 2 Inserm U866, Dijon, F-21000, France 3 EA7269, University of Burgundy, Dijon, F-21000, France 4 Inserm UMR1009, Gustave Roussy Institute, Villejuif F-94805, France 5 University Paris-Sud, Faculty of Medicine, Le Kremlin-Bicetre, F-94800, France Correspondence to: Ali Bettaieb, e-mail: ali.bettaieb@u-bourgogne.fr Keywords: H89, GTN, cancer, purinergic receptors, cGMP Received: October 08, 2014      Accepted: January 09, 2015      Publis…

H89SuraminApoptosisPharmacologyBiologyNitric OxideTransfectionNitric oxideMiceNitroglycerinReceptors Purinergic P2Y1chemistry.chemical_compoundAdenosine TriphosphateCell Line TumorNeoplasmspurinergic receptorsmedicineAnimalsHumanscancerCytotoxic T cellReceptorProtein Kinase InhibitorsMembrane Potential MitochondrialSulfonamidesReceptors Purinergic P2Gene Expression ProfilingPurinergic receptorReceptors PurinergicDrug SynergismOligonucleotides AntisenseIsoquinolinescGMPOncologychemistryApoptosisColonic NeoplasmsCancer cellcardiovascular systemSignal transductionReactive Oxygen SpeciesGTNReceptors Purinergic P2X3circulatory and respiratory physiologySignal TransductionResearch Papermedicine.drugOncotarget
researchProduct

Enhanced antifungal efficacy of tebuconazole using gated pH-driven mesoporous nanoparticles

2014

Núria Mas,1–3 Irene Galiana,3 Silvia Hurtado,† Laura Mondragón,1–3 Andrea Bernardos,1–3 Félix Sancenón,1–3 María D Marcos,1–3 Pedro Amorós,4 Nuria Abril-Utrillas,5 Ramón Martínez-Máñez,1–3 José Ramón Murguía1,3 1Centro de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Centro Mixto Universidad Politécnica de Valencia, Universidad de Valencia, Valencia, Spain; 2Departamento de Química, Universidad Politécnica de Valencia, Valenci…

INGENIERIA DE LA CONSTRUCCIONMaterials scienceAntifungal AgentsPH-responsive nanoparticlesCell Survivalmedia_common.quotation_subjectCapped mesoporous nanoparticlesBiophysicsPharmaceutical ScienceNanoparticleBioengineeringSaccharomyces cerevisiaeNanocapsulesBiomaterialsDiffusionchemistry.chemical_compoundNanoporesQUIMICA ORGANICANanocapsulesInternational Journal of NanomedicineDrug DiscoveryQUIMICA ANALITICABIOQUIMICA Y BIOLOGIA MOLECULARFluoresceinParticle SizeCytotoxicityInternalizationmedia_commonTebuconazoleOriginal ResearchIntracellular releaseOrganic ChemistryQUIMICA INORGANICADrug SynergismGeneral MedicineMesoporous silicaHydrogen-Ion ConcentrationTriazoleschemistryBiochemistryDelayed-Action PreparationsBiophysicsTebuconazole loadingMesoporous materialPorosityInternational Journal of Nanomedicine
researchProduct